Cara Therapeutics Inc
CARA
Get informed when a big investor buys or sells
+ FollowMarket Cap$8.11M
Close$
$0.13
97.6% downside
Current Fair Value
97.6% downsideOvervalued by 97.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $8.11 Million |
|---|---|
| Enterprise Value | $-11,566,447.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.46 |
| Beta | 0.41 |
| Outstanding Shares | 9,381,344,000 |
Return
| Return on Equity | -138.66% |
|---|---|
| Return on Assets | -77.90% |
| Return on Invested Capital | -234.97% |
Valuation & Multiples
| P/E Ratio | -1.6 |
|---|---|
| PEG | -4.13 |
| Price to Sales | -5.32 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 4.5 |
| Enterprise Value to EBIT | 0.34 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.02 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
November 13, 2025
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Cara Therapeutics Inc
CEO: Derek Chalmers